The stock of Bristol-Myers Squibb Company (NYSE:BMY) increased by $0.47 on Friday to finish at $61.70, up 0.76 percent. The last five days have seen an average of 12,686,736 shares of common stock traded. 9 times new highs were reached in the current year, with a fall of -$10.34. The average number of shares traded over the last 20 days was 10,699,389, while the average volume over the last 50 days totaled 9,116,500.
BMY stock dropped -0.39% since last month. On 08/08/23, the company’s shares reached a one-month low of $59.71. The stock touched a high of $81.43 on 02/06/23, after rallying from a low of $59.71 in 52 weeks. The price of BMY stock has declined by -14.25% or -$10.34 this year, reaching a new high 9 times. Still, the stock price is down -24.24% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
BMY stock investors should be aware that Bristol-Myers Squibb Company (BMY) stock had its last reported insider trading activity 11 days ago on Aug 03. On Aug 03, EVP, Chief Research Officer Plenge Robert M sold 732 shares at $61.14 each. This transaction resulted in the insider making $44,754. On May 03, VESSEY RUPERT sold 50,385 shares at a price of US$67.06. After the transaction, the insider now owns 47,751 shares. Board Chair and CEO Caforio Giovanni had earlier sold 240,000 shares on Feb 06 for $74.65 a share. The transaction was completed for $17,916,000.
Valuation Metrics
Bristol-Myers Squibb Company (BMY) has a trailing price-to-earnings (P/E) ratio of 16.42. Beta for the stock is 0.41. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.86, the price-to-book (PB) ratio of 4.04, and the price-to-cash flow ratio of 12.04.
Company paid $0.57 per share in dividends, remained unchanged from $0.57 last year. A $0.03 dividend increase was reported on Thursday December 8 2022.
Financial Health
For the three months ended June 29, Bristol-Myers Squibb Company’s quick ratio was 1.30, while its current ratio was 1.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.08, and the total debt to equity ratio is 1.18. As far as profitability goes, gross margin for the trailing twelve months is 77.10% percent. Bristol-Myers Squibb Company’s EBITDA margin for the year ended June 29 was 42.37%, whereas its operating margin stood at 22.00% for the same period. Based on annual data, it had gross profit of $36.02 billion and revenue of $46.16 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BMY’s return on assets (ROA) during the last 12 months has been 8.30%. There was a 11.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 25.00%.
Earnings Surprise
According to Bristol-Myers Squibb Company’s quarterly financial report for the quarter that ended June 29, it had $34.66 billion in total debt versus $358.0 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $11.23 billion, while revenues fell by -5.89% to $11.34 billion. It was predicted that Bristol-Myers Squibb Company’s quarterly earnings would be $1.75, but it ended up being $1.98, beating the consensus by -11.60%. EBITDA was $4.29 billion for the quarter. At the end of Bristol-Myers Squibb Company’s most recent quarter ended June 29, its liabilities totaled 61.46 billion, while its total debt was $39.21 billion. Equity owned by shareholders amounts to $2.09 billion.
Technical Picture
Here’s a quick look at Bristol-Myers Squibb Company’s (BMY) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 49.95%, suggesting the stock is Neutral, with a 11.55% historical volatility rate.
The stochastic %K and %D were 34.70% and 25.64% respectively, while the average true range (ATR) was 1.08. Based on the 14-day stochastic reading of 45.45%, the RSI (14) reading is 46.15%. On the 9-day MACD Oscillator, the stock is at 0.39, and the 14-day reading is at 0.08.
Analyst Ratings
In its analyst report released on July 14, 2023, HSBC Securities began covering Bristol-Myers Squibb Company (NYSE: BMY). The stock was rated as a Reduce by the brokerage firm. Analysts have assigned Bristol-Myers Squibb Company (BMY) an Overweight rating. BMY is a stock that is recommended for selling by 2 brokerage firms, while 12 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 11 others recommend it as a buy.
What is BMY’s price target for the next 12 months?
The current consensus forecast for the stock is between $56.00 and $90.00, with a median target price of $74.50. In analyzing these forecasts, the average price target given by analysts for Bristol-Myers Squibb Company (BMY) is $73.32.
